

Zeynep Hande Turna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7448427/publications.pdf>

Version: 2024-02-01

56
papers

6,577
citations

840776

11
h-index

361022

35
g-index

59
all docs

59
docs citations

59
times ranked

8001
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. <i>Journal of Chemotherapy</i> , 2023, 35, 29-38.	1.5	2
2	Local aromatase activity alterations in breast cancer tissues: A potential way of decision support for clinicians. <i>Experimental and Molecular Pathology</i> , 2021, 118, 104574.	2.1	0
3	A single center's experience of the extra-pulmonary neuroendocrine carcinomas. <i>İstanbul Kültür Sanat Akademisi Dergisi</i> , 2021, 9, 35-40.	0.3	0
4	Approach to G3 Neuroendocrine Tumors. , 2021, 7, 274-277.		0
5	Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 267-272.	0.9	8
6	Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. <i>BMC Cancer</i> , 2020, 20, 259.	2.6	7
7	Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer. <i>The Journal of Breast Health</i> , 2020, 16, 276-281.	1.0	5
8	Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 2062-2063.	0.9	0
9	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , 2019, 393, 1819-1830.	13.7	2,347
10	P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey. <i>Journal of Thoracic Oncology</i> , 2019, 14, S558-S559.	1.1	3
11	Prognostic factors for survival in patients with metastatic malignant melanoma treated with ipilimumab: Turkish Oncology Group study. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1658-1664.	0.9	7
12	PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1 st Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%. <i>Journal of Thoracic Oncology</i> , 2018, 13, S152.	1.1	0
13	A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1223-1228.	2.0	3
14	Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 346-346.	1.6	1
15	Merkel cell carcinoma in Turkey: A multicentric study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21591-e21591.	1.6	0
16	Prognostic value of aldehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas. <i>Bosnian Journal of Basic Medical Sciences</i> , 2018, 18, 313-319.	1.0	5
17	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet</i> , 2017, 389, 255-265.	13.7	3,872
18	Characteristics of Turkish colorectal cancer patients and bevacizumab preference.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15055-e15055.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Outcomes of Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2017, 35, e12517-e12517.	1.6	1
20	Increased Caseload Volume is Associated With Better Oncologic Outcomes After Laparoscopic Resections for Colorectal Cancer. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2016, 26, 49-53.	0.8	7
21	Evaluation of Local CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in Postmenopausal Invasive Ductal Breast Cancer Cases. Biochemical Genetics, 2016, 54, 784-802.	1.7	10
22	Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12656-e12656.	1.6	0
23	Turkish National Gastric Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12645-e12645.	1.6	0
24	Effect of body mass index in gastric cancer patients: Analysis of Turkish national gastric cancer registry.. Journal of Clinical Oncology, 2015, 33, e15056-e15056.	1.6	0
25	Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12653-e12653.	1.6	0
26	Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12657-e12657.	1.6	0
27	Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12654-e12654.	1.6	0
28	Turkish National Colon Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12646-e12646.	1.6	0
29	Non-Metastatic Ewing's Sarcoma Family of Tumors of Bone in Adolescents and Adults: Prognostic Factors and Clinical Outcome-Single Institution Results. Tumori, 2014, 100, 452-458.	1.1	6
30	Neoadjuvant Treatment with Preoperative Radiotherapy for Extremity Soft Tissue Sarcomas: Long-Term Results from a Single Institution in Turkey. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1775-1781.	1.2	3
31	Therapies Targeting Immune Checkpoints in the Treatment of Non-Small Cell Lung Cancer and Its Clinical Implications. Turkish Journal of Immunology, 2014, 2, 16-19.	0.1	0
32	Turkish Breast Cancer Registry: A multicenter epidemiologic study.. Journal of Clinical Oncology, 2014, 32, e12518-e12518.	1.6	0
33	Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma. Journal of Cancer Research and Therapeutics, 2014, 10, 745.	0.9	6
34	Patterns of Complementary and Alternative Medicine Use among Turkish Cancer Patients. Journal of Palliative Medicine, 2013, 16, 383-390.	1.1	27
35	The relation between pathologic complete response and clinical outcome in patients with rectal cancer. Hepato-Gastroenterology, 2013, 60, .	0.5	7
36	Malignant Clinical Presentation of a Benign Granular Cell Tumor of Breast in a Patient with Previously Treated Contralateral Invasive Ductal Carcinoma. Case Reports in Oncological Medicine, 2012, 2012, 1-3.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Extraskelatal Ewing's Sarcoma Family of Tumors in Adults: Prognostic Factors and Clinical Outcome. Japanese Journal of Clinical Oncology, 2012, 42, 420-426.	1.3	57
38	Increasing Role of FDG-PET/CT in Detecting Bone Marrow Metastasis of Solid Tumors in Adults: An Analysis of Ten Patients. World Journal of Oncology, 2012, 3, 271-279.	1.5	3
39	Thromboembolic complications in cancer patients.. Journal of Clinical Oncology, 2012, 30, e21143-e21143.	1.6	0
40	Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK.. Journal of Clinical Oncology, 2012, 30, e19024-e19024.	1.6	1
41	Prognostic significance of CD44 and c-erb-B2 protein overexpression in patients with gastric cancer. Hepato-Gastroenterology, 2012, 59, 2196-201.	0.5	13
42	2104 POSTER Role of FDG-PET/CT in the Evaluation of Bone Marrow Involvement of Solid Tumours. European Journal of Cancer, 2011, 47, S210.	2.8	0
43	Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: report of first case. Archives of Gynecology and Obstetrics, 2010, 282, 587-590.	1.7	5
44	Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center. Medical Oncology, 2010, 27, 1050-1056.	2.5	13
45	How does 18f-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer?. Journal of Clinical Oncology, 2010, 28, 5053-5053.	1.6	0
46	Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Caseâ€”Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 454-457.	1.7	5
47	Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study. Medical Oncology, 2008, 25, 257-263.	2.5	6
48	Determining predominating histologic component in malignant mixed mllerian tumors: is it worth it?. International Journal of Gynecological Cancer, 2008, 18, 809-812.	2.5	17
49	Paraneoplastic pemphigus associated with fludarabine use. Medical Oncology, 2007, 24, 115-118.	2.5	17
50	Thymoma with chronic diarrhea. Medical Oncology, 2007, 24, 119-123.	2.5	5
51	C-reactive protein as an acute phase protein in cancer patients. Medical Oncology, 2007, 24, 338-344.	2.5	15
52	A caseâ€”control study of non-alcoholic fatty liver disease in breast cancer. Medical Oncology, 2007, 24, 367-371.	2.5	36
53	Reactivation of Hepatitis B Virus Infection with Cytotoxic Therapy in Non-Hodgkin's Lymphoma. Medical Oncology, 2004, 21, 67-72.	2.5	39
54	Should Mammographic Screening Be Done in Primary Ovarian Cancer?: A Case Control Study in Turkish Women. Medical Oncology, 2004, 21, 139-144.	2.5	0

#	ARTICLE	IF	CITATIONS
55	Rituximab-Induced Tumor Progression: Does It Really Happen?. Medical Oncology, 2004, 21, 205-206.	2.5	10
56	How prevalent are alterations in bowel habits during menses?. Diseases of the Colon and Rectum, 2001, 44, 300-301.	1.3	7